Phibro Animal Health Maintains FY2027 Adjusted EPS Outlook at $3.41-$3.59
Phibro Animal Health Maintains FY2027 Adjusted EPS Outlook at $3.41-$3.59 Phibro Animal Health m
Related stories
Formycon Revises 2026 Adjusted EBITDA Guidance After Impairments
Formycon reported non-cash impairments of €39 million for FYB201 and €82 million for FYB202, citing increased competition and price pressure. It lowered adjusted EBITDA guidance to
M impact | EARNINGS | Nov 05, 2026, 04:33 PM UTC
Comer Industries Reports 48.2% Revenue Growth, Reaffirms Guidance
Revenue reached €979.9 million in the first nine months of 2026, including €220.6 million from Comtesco; like-for-like growth was 14.9% and EBITDA was €144.9 million.
M impact | EARNINGS | Nov 05, 2026, 04:33 PM UTC
Novavax Pushes Profitability Target to 2029
Novavax pushed its profitability target to 2029. Its shares dipped.
M impact | EARNINGS | Nov 05, 2026, 04:33 PM UTC
Orion management says EU emission allowance timing boosts Q3 2026 adjusted EBITDA
Orion management says EU emission allowance timing boosts Q3 2026 adjusted EBITDA Orion manageme
L impact | EARNINGS | Nov 05, 2026, 04:32 PM UTC
Kelly Services Reports Results for Quarter Ended September 30
The earnings summary was machine-generated from LSEG data. The supplied text provides no results figures.
L impact | EARNINGS | Nov 05, 2026, 04:32 PM UTC
Kearny Financial 3Q 2026: Revenue $45.28M, EPS $0.16 — 10-Q Summary
Kearny Financial’s first-quarter net interest income rose year over year, lifting net income despite higher credit-loss provision and lower noninterest income. Net interest margin
L impact | EARNINGS | Nov 05, 2026, 04:31 PM UTC